Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Genetic Technologies; Exagen Diagnostics; NorDiag, Hain Lifescience

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies released preliminary financial results this week and said that it will report a net profit after tax of A$4.3 million (US$4.3 million) for the half-year ended Dec. 31. The Australian genomic tools firm said that its half-year revenues were more than A$14.2 million, compared to A$5 million for the first half of 2009. In addition, genetic Technologies noted that its cash reserves were around A$8.4 million at the end of the period.

Exagen Diagnostics this week said that it has completed its expansion at the University of New Mexico Science and Technology Park. The firm said over the next year it intends to double its sales force and hire 16 additional employees.

Norwegian firm NorDiag said this week that Hain Lifescience has placed an order for 25 of the firm's Arrow instruments for nucleic acid purification. This is the second year in a row NorDiag has signed an OEM agreement with Hain for the Arrow instruments.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more